Advertisement
JNJ vs PFE
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- JNJ delivered roughly 6% revenue growth in its latest quarter, led by oncology and immunology, while its MedTech segment lagged and drew investor scrutiny.
- PFE has outperformed recently as investors rotate toward defensive, high-yield healthcare names, with a dividend yield near 5.8%.
- The two companies present contrasting profiles: Johnson & Johnson offers diversification and low volatility, while Pfizer trades at a much lower forward earnings multiple but faces a steeper patent cliff.
- Both firms are actively rebuilding their drug pipelines, with oncology a shared growth priority.
- Johnson & Johnson's premium valuation reflects its defensive quality, whereas Pfizer's discount reflects execution and patent-expiry uncertainty.
Introduction
Johnson & Johnson and Pfizer are two of the largest and most closely followed names in global healthcare, yet they sit at very different points in the market cycle. This stock comparison is relevant for investors weighing a diversified, low-volatility healthcare conglomerate against a turnaround-focused pure-play pharmaceutical company trading at a valuation discount. Traders and long-term investors alike may use the contrast to assess relative performance, dividend appeal, and growth durability. By examining recent market activity, business models, and sentiment shifts, this article provides a balanced view of how these two tickers currently compare and where their market positioning may diverge.
JNJ Overview and Recent Performance
Johnson & Johnson operates two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In recent weeks, the company reported third-quarter revenue of approximately $25.4 billion, up about 6% year over year, with adjusted earnings per share (EPS) of $2.59. Innovative Medicine grew nearly 8% operationally, powered by oncology (up roughly 17%) and strong contributions from treatments such as TREMFYA, while MedTech rose only about 2.5% and missed expectations for a second consecutive quarter. Management raised its full-year sales outlook while also announcing a proposed settlement of ovarian talc litigation. The stock has climbed substantially over the trailing year but pulled back in the recent month as investors weighed MedTech softness and a premium valuation against a steadily growing pharma franchise and a dividend track record spanning more than six decades.
PFE Overview and Recent Performance
Pfizer is a research-based biopharmaceutical company with a portfolio spanning oncology, vaccines, immunology, and cardiovascular treatments. After years of post-pandemic underperformance, the stock has regained momentum in recent market activity, advancing roughly 18% year to date in what is shaping up to be its strongest year since 2021, while still trading well below its five-year peak. The shares have benefited from a rotation into higher-yielding, defensive healthcare stocks, with a forward dividend yield near 5.8%. The company faces a meaningful patent cliff, with key products such as Eliquis and Xeljanz losing exclusivity, and has leaned on oncology assets like Padcev and Lorbrena, a large collaboration with Innovent, and cost-cutting programs to rebuild growth. Activist investor pressure has added a layer of scrutiny around execution.
Trending AI Robots
For traders who prefer a systematic, data-driven approach, Tickeron's Trending AI Robots page offers a curated view of the platform's most compelling automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group earns a place in this section at any given time. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of tickers, giving users a range of approaches to explore. By focusing on the bots best suited to current market conditions, the page helps traders identify signals and strategies that are actively performing rather than sifting through the entire catalog. Explore the Trending AI Robots section to see which automated strategies are currently standing out.
Head-to-Head Comparison
The clearest contrast between these two names is diversification versus concentration. Johnson & Johnson's device business and broad pharma portfolio provide multiple revenue streams and a low beta, meaning its shares tend to move less than the broader market. Pfizer is more exposed to the timing of individual drug launches and patent expirations, which creates both greater risk and greater potential for re-rating. On valuation, Pfizer trades at a forward price-to-earnings (P/E) multiple near 10, well below Johnson & Johnson's roughly 21x, reflecting the market's lower confidence in Pfizer's near-term earnings durability. On income, Pfizer's roughly 5.8% yield far exceeds Johnson & Johnson's near 2%, but Johnson & Johnson's payout has grown for decades without interruption, while Pfizer's dividend was cut during the 2009 financial crisis. Recent momentum favors Pfizer amid the defensive rotation, while Johnson & Johnson's relative performance has cooled following its MedTech miss.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor JNJ on trend consistency and stability, given its diversified revenue base, low volatility, and long record of dividend growth, even though its near-term momentum has moderated. Pfizer's higher yield, lower valuation, and improving relative strength make it a compelling candidate for a momentum or value-oriented signal, but its patent-cliff exposure and execution uncertainty introduce greater variability. In probabilistic terms, the AI would lean toward Johnson & Johnson as the more consistent, lower-risk positioning, while recognizing Pfizer as the higher-potential, higher-uncertainty alternative for traders comfortable with volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Hold and PFE is a StrongBuy.
JNJ's RSI Oscillator climbs out of oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 14 of the 30 cases the stock moved higher. This puts the odds of a move higher at 47%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 21 of 47 cases over the following month. The odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
JNJ moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.482) is normal, around the industry mean (-2.730). P/E Ratio (30.219) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.040) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
PFE in +1.27% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 41 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 47%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 17 of 43 cases over the following month. The odds of a continued upward trend are 40%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 14 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (-2.730). P/E Ratio (39.000) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.057) settles around the average of (0.040) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
JNJ | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 37 | 83 | |
PRICE GROWTH RATING 1..100 | 43 | 15 | |
P/E GROWTH RATING 1..100 | 7 | 3 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (77) in the Pharmaceuticals Major industry is in the same range as PFE (93). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
JNJ's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (15) in the Pharmaceuticals Major industry is in the same range as JNJ (43). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as JNJ (7). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | PFE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 1 day ago 52% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 46% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 45% | 1 day ago 40% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 45% | 1 day ago 49% |
| Advances ODDS (%) | 13 days ago 46% | 9 days ago 54% |
| Declines ODDS (%) | 20 days ago 40% | 20 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 31% | 1 day ago 52% |
| Aroon ODDS (%) | 1 day ago 38% | 1 day ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- JNJ’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- JNJ’s TA Score: 4 bullish, 6 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +3.23% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.28% | ||
| BMY - PFE | 57% Loosely correlated | -2.41% | ||
| AMGN - PFE | 52% Loosely correlated | -1.79% | ||
| NVS - PFE | 49% Loosely correlated | -3.30% | ||
| BIIB - PFE | 48% Loosely correlated | -1.24% | ||
| SNY - PFE | 47% Loosely correlated | -0.86% | ||
More | ||||